Patents by Inventor Friedrich Dorner

Friedrich Dorner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEDIUM FOR THE PROTEIN-FREE AND SERUM-FREE CULTIVATION OF CELLS
    Publication number: 20080182297
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 31, 2008
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Animal protein-free media for cultivation of cells
    Publication number: 20080064105
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: October 30, 2007
    Publication date: March 13, 2008
    Applicant: Baxter Healthcare Corporation
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Animal protein-free media for cultivation of cells
    Publication number: 20080064080
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: October 30, 2007
    Publication date: March 13, 2008
    Applicant: Baxter Healthcare Corporation
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
    Publication number: 20080009040
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: September 20, 2007
    Publication date: January 10, 2008
    Applicant: Baxter Healthcare Corporation
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Patent number: 7279161
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: October 9, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
  • Recombinant cell clones having increased stability and methods of making and using the same
    Publication number: 20070161079
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: July 7, 2006
    Publication date: July 12, 2007
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Enveloped virus vaccine and method for production
    Publication number: 20070141617
    Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.
    Type: Application
    Filed: January 24, 2007
    Publication date: June 21, 2007
    Applicant: Baxter Healthcare S.A.
    Inventors: Otfried Kistner, Manfred Reiter, Axel Bruehmann, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Nucleic acids encoding factor X analogues having a modified protease cleavage site
    Patent number: 7220569
    Abstract: Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: May 22, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
  • Enveloped virus vaccine and method for production
    Patent number: 7195905
    Abstract: The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: March 27, 2007
    Assignee: Baxter Healthcare S.A.
    Inventors: Otfried Kistner, Manfred Reiter, Axel Bruehmann, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 7094574
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: August 22, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Inactivated influenza virus vaccine for nasal or oral application
    Publication number: 20060147468
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Application
    Filed: March 2, 2006
    Publication date: July 6, 2006
    Applicant: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Inactivated influenza virus vaccine for nasal or oral application
    Patent number: 7052701
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: May 30, 2006
    Assignee: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Animal protein-free media for cultivation of cells
    Publication number: 20060094104
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 4, 2006
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Patent number: 7033590
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 25, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
  • Method for purifying factor VIII/vWF-complex by means of cation exchange chromatography
    Publication number: 20050239171
    Abstract: There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex , which particularly contains high-molecular vWF multimers, as well as a factor VIII/vWF-complex obtainable by means of cation exchange chromatography.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 27, 2005
    Applicant: Baxter Aktiengesellschaft
    Inventors: Artur Mitterer, Bernhard Fischer, Oyvind Schonberger, Kathrin Thomas-Urban, Friedrich Dorner, Johann Eibl
  • Factor VIII/vWF complexes and compositions
    Patent number: 6953837
    Abstract: There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex, which particularly contains high-molecular vWF multimers, as well as a factor VIII/vWF-complex obtainable by means of cation exchange chromatography.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: October 11, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Artur Mitterer, Bernhard Fischer, Öyvind L. Schönberger, Kathrin Thomas-Urban, Friedrich Dorner, Johann Eibl
  • Stable factor VIII/von Willebrand factor complex
    Publication number: 20050209154
    Abstract: There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex.
    Type: Application
    Filed: May 19, 2005
    Publication date: September 22, 2005
    Applicant: Baxter Aktiengesellschaft
    Inventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Johann Eibl
  • Recombinant cell clones having increased stability and methods of making and using the same
    Publication number: 20050196843
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: May 6, 2005
    Publication date: September 8, 2005
    Applicants: Baxter Aktiengesellschaft, Baxter Healthcare Corporation
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Inactivated influenza virus vaccine for nasal or oral application
    Publication number: 20050196413
    Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.
    Type: Application
    Filed: January 4, 2005
    Publication date: September 8, 2005
    Applicant: Baxter Healthcare S.A.
    Inventors: Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 6936441
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: August 30, 2005
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner